Anti-cd40 antibodies, uses and methods
AssigneeAlligator Bioscience AB
InventorsPeter Bo Joakim Ellmark, Eva Maria Dahlen
Life of this patent
Estimating the term…
Abstract
The present invention relates to antibodies (and fragments, variants, fusions and derivatives thereof) with multivalent binding specificity for CD40, which have a potency for dendritic cell activation which is higher than, or is equal to, the potency for B cell activation and wherein the antibody, antigen-binding fragment, or fusion, variant or derivative thereof has an affinity (KD) for CD40 of less than 1×10−10 M, which have utility in the treatment of diseases such as cancer. The invention also relates to pharmaceutical compositions, uses, methods and kits comprising such antibodies.
Claims39
An antibody or an antigen-binding fragment thereof with multivalent binding specificity for CD40,
- or a variant, fusion or derivative of said antibody or antigen-binding fragment, or a fusion of a said variant or derivative thereof, which retains the multivalent binding specificity for the CD40,
- wherein the potency of the antibody, antigen-binding fragment, or fusion, variant or derivative thereof, for dendritic cell activation is higher than, or is equal to, its potency for B cell activation and/or wherein the antibody, antigen-binding fragment, or fusion, variant or derivative thereof has an affinity (KD) for CD40 of less than 1×10−10 M.
(canceled)
(canceled)
(canceled)
8-10. (canceled)
(canceled)
15-17. (canceled)
(canceled)
(canceled)
23-25. (canceled)
28-30. (canceled)
(canceled)
(canceled)
41-49. (canceled)
51-60. (canceled)
62-68. (canceled)
70-75. (canceled)
Dependencies are inferred from the claim text.